In clinical practice, EGFR mutation assessment is recommended to guide target therapy for NSCLC patients, and ctDNA is a promising biomarker for noninvasive EGFR mutation detection as well as other molecular testing for personalized cancer management[19–27]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.